RELB Antibodies

Target Information

a subunit of NF-kappa-B transcription complex (NFkB), which plays a crucial role in biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NFkB consists of homo- or heterodimeric complexes formed from the five NFkB proteins in mammals: RelA, RelB, c-REL, NFkB1, and NFkB2. They form a variety of homodimers and heterodimers, each binding at kappa-B sites in the DNA, regulating distinct sets of genes. Different dimer combinations act as transcriptional activators or repressors. Stimulates promoter activity in the presence of isoform 3 of NFKB2. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Is required for both T and B lymphocyte maturation and function. Note: This description may include information from UniProtKB.

Alternate Names

avian reticuloendotheliosis viral (v-rel) oncogene related B; I-Rel; IMD53; IREL; MGC143683; MGC143684; OTTMUSP00000022318; REL-B; RELB; Relb; RELB proto-oncogene, NF-kB subunit; shep; Transcription factor RelB; v-rel avian reticuloendotheliosis viral oncogene homolog B (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3); v-rel reticuloendotheliosis viral oncogene homolog B; v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3